ArticleMedical oncology (Northwood, London, England)2026
CD168 in lung adenocarcinoma: prognostic relevance, immune feature associations, and MAPK/ERK pathway enrichment.
Article in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Lung adenocarcinoma (LUAD), the predominant non-small cell lung cancer (NSCLC) subtype, faces major clinical challenges including poor prognosis and acquired drug resistance. This study integrates multi-omics analyses with in vitro functional validation experiments to systematically elucidate the molecular regulatory mechanisms of hyaluronan receptor (RHAMM/CD168) in LUAD development and its potential clinical translational value. Bioinformatics analysis based on public databases such as TCGA and GEO revealed that CD168 mRNA expression was significantly higher in LUAD tumor tissues compared to adjacent normal tissues. Kaplan-Meier survival analysis and multivariable Cox regression models confirmed that high CD168 expression was independently associated with significantly shorter overall survival (OS) and progression-free survival (PFS) after adjusting for confounding factors such as age, gender, and clinical stage. Moreover, high CD168 expression correlated with altered immune cell infiltration patterns and changes in immune checkpoint molecule expression, suggesting that CD168 may play a crucial role in modulating the immune-suppressive tumor microenvironment and affecting responses to immunotherapy. Functional experiments demonstrated that silencing CD168 significantly inhibited cell proliferation, migration, and invasion in LUAD cell lines (A549 and H1299), and promoted apoptosis, confirming its oncogenic function. Bioinformatics analysis constructed the "lncRNA (CYTOR)-miRNA (hsa-let-7c-5p)-CD168" regulatory axis, wherein CYTOR may function as a ceRNA to sequester hsa-let-7c-5p, thereby alleviating miRNA-mediated suppression of CD168. Furthermore, Western blot analysis revealed that silencing CD168 decreased the phosphorylation levels of ERK and MEK, suggesting that CD168 promotes LUAD progression in association with MAPK/ERK signaling pathway activity. In summary, CD168 may promote LUAD progression by reshaping the immunosuppressive microenvironment and enhancing malignant behavior, establishing it as a prognostic biomarker and a potential therapeutic target, particularly for immunotherapy combinations.
Indexed as
Identifiers
41652128What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.